Dr Hwang reviews key findings of research he presented at ACR Convergence on inflammatory back pain and the importance of multimodality evaluation to identify patients with axial spondyloarthritis vs mechanical back pain.
Dr Hwang reviews key findings of research he presented at ACR Convergence on inflammatory back pain and the importance of multimodality evaluation to identify patients with axial spondyloarthritis vs mechanical back pain.
A phase III randomized trial showed QX002N significantly improved clinical outcomes and MRI-assessed inflammation in patients with radiographic axSpA, with a favorable safety profile.
A phase III randomized trial showed QX002N significantly improved clinical outcomes and MRI-assessed inflammation in patients with radiographic axSpA, with a favorable safety profile.
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
An 8-week individualized training program led to significant improvements in trunk function and aerobic capacity in patients with axSpA, offering rheumatologists new data to support exercise-based interventions.
An 8-week individualized training program led to significant improvements in trunk function and aerobic capacity in patients with axSpA, offering rheumatologists new data to support exercise-based interventions.
The European Alliance of Associations for Rheumatology (EULAR) updated its 2019 guideline for the management of psoriatic arthritis to integrate new data and therapies.
The European Alliance of Associations for Rheumatology (EULAR) updated its 2019 guideline for the management of psoriatic arthritis to integrate new data and therapies.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
